Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure : The EMPIRICUS Randomized Clinical Trial

This randomized clinical trial has lead to a practice changing update on Dynamed Plus. It compares the effects of micafungin vs placebo on 28-day fungal infection –free survival among nonneutropenic critically ill patients with ICU-acquired sepsis, Candida species colonization at multiple sites, and multiple organ failure. It concludes that empiric micafungin does not improve 28-day fungal infection-free survival in nonneutropenic patients with ICU-acquired sepsis.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news